N-methyl-D-aspartate antagonists as drug models of schizophrenia: A surprising link to tobacco smoking

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 5, 2004, Pages 801-811

  Domino, Edward F ^a   Mirzoyan, Diana ^a   Tsukada, Hideo ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Dopamine; Glutamic acid; Nicotine; NMDA antagonists; Schizophrenia; Serotonin; Tobacco smoking

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ATROPINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINE; SEROTONIN; SEROTONIN ANTAGONIST; VALPROIC ACID;

BINDING AFFINITY; BRAIN FUNCTION; CIGARETTE SMOKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN CHEMISTRY; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MODELS, BIOLOGICAL; NEUROTRANSMITTER AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SMOKING;

EID: 4444249969     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.05.024     Document Type: Review

References (141)

1. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Heertum R.V., Gorman J.M., Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22:2002;3708-3719
2. Abi-Dargham A., Narendran R., Frankle G., Khenissi L., Gil R., Cooper T., Hwang D.-R., Erritzoe D., Huang Y., Martinez D., Caton C., Laurelle M. PET imaging of prefrontal dopamine D1 receptors in chronic PCP/ketamine human abusers: a model for schizophrenia. Sci. Abstr., Am. Coll. Neuropsychopharmacol. 2003;3
3. Abi-Saab W.M., D'Souza D.C., Moghaddam B., Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 31(suppl.):1998;S104-S109
4. Abraham H.D., McCann U.D., Ricaurte G.A. Psychedelic drugs. Davis K.L., Charney D., Coyle J.T., Nemeroff C. Neuropsychopharmacology: The Fifth Generation of Progress. 2002;1545-1556 Lippincott Williams and Wilkins, Philadelphia
5. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry. 17:1982;639-654
6. Adler L.E., Hoffer L.J., Griffith J., Waldo M., Freedman R. Normalization of deficient auditory sensory gating in the relatives of schizophrenics by nicotine. Biol. Psychiatry. 32:1992;607-616
7. Adler L.E., Hoffer L.J., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry. 150:1993;1856-1861
8. Adler L.E., Olincy A., Waldo, Harris J.G., Griffith J., Stevens K., Flach K., Nagomoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotine receptors. Schizophr. Bull. 24:1998;189-202
9. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1083
10. Andreasen N.C. The diagnosis of schizophrenia. Schizophr. Bull. 13:1987;9-22
11. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients. Lancet. 349:1997;1730-1734
12. Angrist B., van Kammen D.P. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7:1984;388-390
13. Benwell M.E., Balfour D.J. The effects of nicotine administration on 5-HT uptake and biosynthesis in rat brain. Eur. J. Pharmacol. 84:1982;71-77
14. Berman K.F., Meyer-Lindenberg A. Chap. 23. Functional brain imaging studies in schizophrenia. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;311-323 Oxford Univ. Press, New York
15. Blackwood D.H., Whalley L.J., Christie J.E., Blackburn I.M., St Clair D.M., McInnes A. Changes in auditory P3 event-related potential in schizophrenia and depression. Br. J. Psychiatry. 150:1987;154-160
16. Braff D.L. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 19:1993;233-259
17. Braff D.L. Chap. 24. Psychophysiological and information processing approaches to schizophrenia. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;324-338 Oxford Univ. Press, New York
18. Braff D.L., Freedman R. Chap. 51. Endophenotypes in studies of the genetics of schizophrenia. Davis K.L., Charney D., Coyle J.T., Nemeroff C. Neuropsychopharmacology. The Fifth Generation of Progress. 2002;703-716 Lippincott Williams and Wilkins, Philadelphia
19. 3H)nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282:1997;7-13
20. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., Marks M.J., Collins A.C., Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology. 23:2000;351-364
21. Breir A. Chap. 18. Diagnostic classification of the psychoses: historical context and implications for neurobiology. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;237-246 Oxford Univ. Press, New York
22. Brown S., Inskip H., Barraclough B. Causes of excess mortality of schizophrenia. Br. J. Psychiatry. 177:2000;212-217
23. Cadenhead K.S., Swerdlow N.R., Shafer K.M., Diaz M., Braff D.I. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and schizotypal disordered subjects: evidence of inhibitory deficits. Am. J. Psychiatry. 157:2000;1660-1668
24. Carboni G., Dong E., Pesold C., Tueting P., Li X., Costa E., Guidotti A. Heterozygous reeler mice (rl+/-) display increased cognitive impairment when treated with dizolcipine. Soc. Neurosci. Abs. 26(396.12):2000;1058
25. Carlsson A. Does dopamine play a role in schizophrenia? Psychol. Med. 7:1977;583-597
26. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186
27. Carlsson A. Reply to commentaries on "The current status of the dopamine hypothesis of schizophrenia" Neuropsychopharmacology. 1:1988;201-203
28. Chen Y., Sharma R.P., Costa R.H., Costa E., Grayson D.R. On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res. 30:2002;2930-2939
29. Choy G.A., Lewis D.A. Chap. 22. The neurobiology of schizophrenia. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;299-310 Oxford Univ. Press, New York
30. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S., Yellen D. Comparison of Sernyl with other drugs: I. Attention, motor function, and proprioception. Arch. Gen. Psychiatry. 1:1959;651-656
31. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S. Combined Sernyl and sensory deprivation. Compr. Psychiatry. 1:1960;345-348
32. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs: II. Symbolic and sequential thinking. Arch. Gen. Psychiatry. 6:1962;395-401
33. Cohen S.M., Nichols A., Wyatt R., Pollin W. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol. Psychiatry. 8:1974;209-225
34. Collins A.C., Luo Y., Selvaag S., Marks M.J. Sensitivity to nicotine and brain nicotinic receptors are altered by chronic nicotine and mecamylamine infusion. J. Pharmacol. Exp. Ther. 271:1994;125-133
35. Costa E., Davis J., Grayson D.R., Guidotti A., Pappas G.D., Pesold C. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiology. 8:2001;723-742
36. Costa E., Chen Y., Davis J., Dong E., Noh J.S., Tremolizzo L., Veldic M., Grayon D.R., Guidotti A. Reelin and schizophrenia: a disease at the interface of the genome and epigenome. Mol. Interv. 2:2002;47-57
37. Costa E., Davis J., Pesold C., Tueting P., Guidotti A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr. Opin. Pharmacol. 1:2002;56-62
38. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology. 2004;. (Submitted for publication)
39. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 19:1976;481-483
40. Dalack B.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatry. 1555:1998;1490-1501
41. Davies B.M., Beech H.R. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J. Ment. Sci. 106:1960;912-924
42. Domino E.F. Indoleakylamines as psychotogen precursors - possible neurotransmitter imbalance. Domino E.F., Davis J.M. Neurotransmitter Balances Regulating Behavior. 1975;185-228 NPP Books, Ann Arbor, MI, Box 1491, 48106
43. Domino E.F. The indole hallucinogen model: is it worth pursuing? Sudilovsky A., Gershon S., Beer B. Predictability in Psychopharmacology: Preclinical and Clinical Correlations. 1975;247-268 Raven Press, New York
44. Domino E.F. Indole hallucinogens as animal models of schizophrenia. Serban G., Kling A. Animal Models in Human Psychobiology. 1976;239-259 Plenum, New York
45. Domino E.F. PCP (Phencyclidine): Historical and Current Perspectives. 1981;1-537 NPP Books, Ann Arbor, MI
46. Domino E.F. Monoamine oxidase, tobacco smoking and psychiatric disorders. Biol. Psychiatry. 40:1996;433-434
47. Domino E.F. Conflicting evidence for the dopamine release theory of nicotine/tobacco dependence. Nihon Shinkei (Jpn. J. Neuropsychopharmacol.). 22:2002;181-184
48. 14C-tryptamine in whole blood of mentally normal controls and drug-free chronic schizophrenic patients. Am. J. Psychiatry. 134:1977;1280-1282
49. Domino E.F., Khanna S.S. Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients. Am. J. Psychiatry. 133:1976;323-326
50. Domino E.F., Kishimoto T. Tobacco smoking increases gating of irrelevant and enhances attention to relevant tones. Nicotine Tob. Res. 4:2002;71-78
51. Domino E.F., Luby E.D. Abnormal mental states induced by phencyclidine as a model of schizophrenia. Domino E.F. PCP (Phencyclidine): Historical and Current Perspectives. 1981;401-418 NPP Books, Ann Arbor
52. Esiri M.M., Crow T.J. Chap. 7. Neuropathology of psychiatric disorders. 7th ed. Graham D.I., Lantos P.L. Greenfield's Neuropathology. vol. 2:2002;431-470 Arnold, New York
53. Fauman M.A., Fauman B.J. The psychiatric aspects of chronic phencyclidine use: a study of chronic PCP users. NIDA Res. Monogr. 21:1978;183-200
54. Forrer G.R., et al. Symposium on atropine toxicity therapy. J. Nerv. Ment. Dis. 124:1956;256-280
55. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736
56. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14059-14065
57. Freedman R., Mirsky A.F. Event-related potentials: exogenous components. Steinhauser S.R., Gruzelier Z.H., Zubin J. Neuropsychology, Psychophysiology, and Information Processing. Handbook of Schizophrenia. vol. 5:1991;71-90 Elsevier, Amsterdam
58. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol. Psychiatry. 18:1983;537-551
59. Freedman R., Adler L.E., Gerhardt G.A., Waldo M., Baker N., Rose G.G., Drebing C., Nagamoto H., Bickford-Wimer P., Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophr. Bull. 13:1987;669-678
60. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A. 94:1997;587-592
61. Friedhoff A.J. Dopamine as a mediator of a central stabilizing system. Neuropsychopharmacology. 1:1988;189-191
62. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., Barnes T.R., Hirsch S.R. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry. 65:1998;446-453
63. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 57:2000;65-73
64. Glassman A.H. Cigarette smoking: implications for psychiatric illness. Am. J. Psychiatry. 150:1993;546-553
65. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377
66. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am. J. Psychiatry. 149:1992;1180-1194
67. Goldman-Rakic P.S. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6:1994;348-357
68. Guidotti A., Auta J., Davis J.S., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., Costa E., DiGiorgi L., Gerevini V. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry. 57:2000;1061-1069. (Erratum in Arch. Gen. Psychiatry 59, 12)
69. Guidotti A., Pesold C., Costa E. New neurochemical markers for psychosis: a working hypothesis of their operation. Neurochem. Res. 25:2000;1207-1218
70. Harrison P.J. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 122:1999;593-624
71. Holzman P.S., Proctor L.R., Hughes D.W. Eye-tracking patterns in schizophrenia. Science. 181:1973;179-181
72. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., Uzunov D.P., Smalheiser N.R., Davis J.M., Pandey G.N., Pappas G.D., Tueting P., Sharma R.P., Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15718-15723
73. Jacobi W., Winkler H. Encephalograhische sutdien an chronish schizophrenen. Arch. Psychiatr. Nervenkr. 81:1927;299-332
74. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308
75. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
76. Johnstone E.C., Crow T.J., Frith C.D., Husband J., Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 2:1976;924-926
77. Kane J., Honigfeld G., Singer J., Meltzer H.Y. The Clozaril Collaborative Study Group Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796
78. Kety S.S. The significance of genetic factors in the etiology of schizophrenia: results from the national study of adoptees in Denmark. J. Psychiatr. Res. 21:1987;423-429
79. Kety S.S., Rosenthal D., Wender P.H., Schulsinger F., Jacobsen B. The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics. J. Psychiatr. Res. 6:1968;345-362
80. Kety S.S., Wender P.H., Jacobsen B., Ingraham L.J., Jansson L., Faber B., Kinney D.K. Mental illness in the biological and adoptive relatives of schizophrenic adoptees: replication of the Copenhagen study in the rest of Denmark. Arch. Gen. Psychiatry. 51:1994;442-455
81. Klein D.F. Rheostat and cybernetic issues. Neuropsychopharmacology. 1:1988;187-188
82. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214
83. Krystal J.E., Abi-Dargham A., Laruelle M., Moghaddam B. Chap. 21. Pharmacological models of psychoses. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;287-298 Oxford Univ. Press, New York
84. Kumari V., Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology. 162:2002;97-101
85. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13:1999;358-371
86. Laruelle M., Martinez D., Talbot P.S., Abi-Dargham A. Molecular imaging in psychiatric disorders. Valk P.E., Bailey D.L., Townsend D.W., Maisey M.N. Positron Emission Tomography: Basic Science and Clinical Practice. 2002;399-426 Springer, London
87. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22:1996;431-445
88. Leonard S., Adler L.E., Benhammou K., Berger R., Breese C.R., Drebing C., Gault J., Lee M.J., Logel J., Olincy A., Ross R.G., Stevens K., Sullivan B., Vianzon R., Virnich D.E., Waldo M., Walton K., Freedman R. Smoking and mental illness. Pharmacol., Biochem. Behav. 70:2001;561-570
89. Lodge D., Aram J.A., Church J., Davies S.N., Fletcher E., Martin D. Domino E.F., Kamenka J.-M. Electrophysiological Studies of the Interaction Between Phencyclidine/Sigma Receptor Agonists and Excitatory Amino Acid Neurotransmission on Central Mammalian Neurons. 1988;239-250 NPP Books, Ann Arbor
90. Luby E.D. Chap. 4. Phencyclidine revisited. Domino E.F. PCP (Phencyclidine): Historical and Current Perspectives. 1981;25-30 NPP Books, Ann Arbor, MI
91. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug - Sernyl. Arch. Neurol. Psychiatry. 81:1959;363-369
92. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychoses and schizophrenia. Am. J. Psychiatry. 119:1962;61-67
93. Luisada P.V. The phencyclidine psychosis: phenomenology and treatment. NIDA Res. Monogr. 21:1978;241-253
94. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307
95. Marks M.J., Burch J.B., Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther. 226:1983;817-825
96. Matherson E., O'Shea B. Smoking and malignancy in schizophrenia. Br. J. Psychiatry. 145:1984;429-432
97. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia. Fed. Proc. 32:1973;200-205
98. McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Fischer I.A., Shenton M.E. MRI anatomy of schizophrenia. Biol. Psychiatry. 45:1999;1099-1119
99. McDonald J.W., Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Rev. 15:1990;41-70
100. Meltzer H.A. New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacology. 1:1988;193-196
101. Meltzer H.Y., Bastani B., Ramirez L., Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur. Arch. Psychiatr. Neurol. Sci. 238:1989;332-339
102. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246
103. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 28:2000;53-67
104. Miyasaka M., Domino E.F. Neuronal mechanisms of ketamine-induced anesthesia. Int. J. Neuropharmacol. 7:1968;557-573
105. Morgan C.J.A., Mofeez A., Brandner B., Bromley L., Curran H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology. 29:2004;208-218
106. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Kelly Melson A., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology. 20:1999;106-118
107. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 386:1997;634-636
108. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007
109. Olney J.W., Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 13:1995b;335-345
110. Pearlson G.D., Marsh L. Structural brain imaging in schizophrenia: a selective review. Biol. Psychiatry. 46:1999;627-649
111. Powers R.E. The neuropathology of schizophrenia. J. Neuropath. Exp. Neurol. 58:1999;679-690
112. Reynolds G.P., Beasley C.L. GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J. Chem. Neuroanat. 22:2001;95-100
113. Reynolds G.P., Zhang Z.J., Beasley C.L. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective loses of calcium binding protein immunoreactivity. Brain Res. Bull. 55:2001;579-584
114. Riley B., Kindler K. Chap. 19. Molecular genetics of schizophrenia. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;247-262 Oxford Univ. Press, New York
115. Robbins T.W. Chap. 20. Animal models of the psychoses. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;263-286 Oxford Univ. Press, New York
116. Rodin E.A., Luby E.D., Meyer J.S. Electroencephalographic findings associated with Sernyl infusion. EEG Clin. Neurophysiol. 11:1959;796-798
117. Rodriguez M.A., Pesold C., Liu W.S., Kriho V., Guidotti A., Pappas G.D., Costa E. Colocalization of integrin receptors and reelin in dendritic spine postsynaptic densities of adult nonhuman primate cortex. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3550-3555
118. Rosse R.B., Collins J.P. Jr., Fay-McCarthy M., Alim T.N., Wyatt R.J., Deutsch S.I. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin. Neuropharm. 17:1994;359-369
119. Saletu B., Itil T.M., Saletu M. Auditory evoked response, EEG, and thought process in schizophrenics. Am. J. Psychiatry. 128:1971;336-344
120. Sawa A., Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science. 296:2002;692-695
121. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 251:1991;947-950
122. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71:1994;515-528
123. Schwartz R.D., Kellar K.J. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science. 220:1983;214-216
124. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 188:1975;1217-1219
125. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719
126. Selemon I.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit-based model of schizophrenia. Biol. Psychiatry. 45:1999;17-25
127. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 49:2001;1-52
128. Snyder S.H. Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Am. J. Psychiatry. 130:1973;61-67
129. Snyder S.H. Psychotropic drugs as models of schizophrenia. Neuropsychopharmacology. 1:1988;197-199
130. Stockard J.J., Werner S.S., Aalbers J.A., Chiappa K.H. Electroencephalographic findings in phencyclidine intoxication. Arch. Neurol. 33:1976;200-203
131. Taminga C.A. Chap. 25. Principles of the pharmacotherapy of schizophrenia. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;339-354 Oxford Univ. Press, New York
132. Tandon R. Cholinergic aspects of schizophrenia. Br. J. Psychiatry. 174(suppl. 37):1999;7-11
133. Tremolizzo L., Carboni G., Ruzicka W.B., Mitchell C.P., Sugaya I., Tueting P., Sharma R., Grayson D.R., Costa E., Guidotti A. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. U. S. A. 99:2002;17095-17100
134. Tsukada H., Domino E.F. NMDA antagonisms impairs dopamine system in prefrontal cortex: PET study with conscious monkeys. Sci. Abstr., Am. Coll. Neuropsychopharmacol. 2003;3
135. 11C]raclopride binding in unanesthetized monkeys. Synapse. 45:2002;207-212
136. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44:1987;660-669
137. Weinberger D.R. Editor, Section III. Psychoses. Charney D.S., Nestler E.J. Neurobiology of Mental Illness. 2nd ed.:2004;233-236 Oxford Univ. Press, New York
138. Weinberger D.R., Torrey E.F., Neophytides A.N., Wyatt R.J. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch. Gen. Psychiatry. 36:1979;735-739
139. Weinberger D.R., Berman K.F., Zec R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. regional cerebral blood flow (rCBF) evidence. Arch. Gen. Psychiatry. 43:1986;114-125
140. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. 11:1990;216-219
141. Wright I.E., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry. 157:2000;16-25